Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

NCT05280314 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: IO102-IO103
DRUG: Pembrolizumab KEYTRUDA®

Sponsor

IO Biotech

Collaborators

[object Object]
[object Object]
[object Object]